Helen Parrott
Clinical Lead, NuvoAir
Validated technology allows patients to monitor respiratory health from home.
Around 200,000 people in the UK have severe asthma, a serious and often debilitating form of asthma that’s not easy to manage, as patients are often unresponsive to conventional treatments.
Coughing, wheezing and breathlessness can affect everyday life such as work, study and relationships. People with severe asthma often spend their lives in and out of hospitals.
Regular monitoring of lung function, symptoms and treatment is key to finding the right management course for each individual. A visit to a specialist asthma centre or clinic for tests such as spirometry can be required several times a year.
With COVID-19 affecting healthcare’s ability to maintain check-up appointments, and people less willing to attend, wouldn’t it be faster, safer and more efficient if patients could effectively monitor their health at home?
Technology enables patient home monitoring
There is a rise in new medical device technology that gathers health data remotely. This means people can self-monitor from home and share data with their care teams for timely decision-making.
Wouldn’t it be faster, safer and more efficient if patients could effectively monitor their health at home?
New possibilities for clinicians
Is there technology that can be trusted? NuvoAir has developed a respiratory platform which includes a home spirometer and app that provides coaching to achieve quality results. Peer-reviewed studies and clinical evidence have proven the validity of the technology and show that unsupervised home spirometry with NuvoAir is equivalent to in-clinic spirometry, with high adherence and engagement.
Clinicians can review data in real time, allowing swift interventions and therapy changes, without waiting months for an appointment. For people with severe asthma, this brings potential for substantially improved quality of life.
Having real-time access to respiratory health data means clinicians can identify patients that might benefit from new biologic treatments sooner. Being data driven helps to measure the effectiveness of interventions and new treatments. Symptoms and quality of life data help clinicians to get a holistic view.
There are also benefits for transforming clinical services. A study involving cystic fibrosis patients at the Royal Brompton Hospital showed a 39% reduction in urgent face-to-face visits and 31% reduction in booked face-to-face visits with virtual consultations supported by NuvoAir before COVID-19.
The NuvoAir Home platform contains a toolkit of devices and features that enables home monitoring and optimal care for people with severe respiratory conditions. The platform is used by hundreds of clinicians and thousands of patients in the UK alone and can benefit patients with severe asthma, cystic fibrosis, COPD and other respiratory conditions.
